Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer

Although immunotherapy has led to durable responses in diverse cancers, unfortunately, there has been limited efficacy and clinical response rates due to primary or acquired resistance to immunotherapy. To maximize the potential of immunotherapy, combination therapy with antiangiogenic drugs seems t...

Descripción completa

Detalles Bibliográficos
Autores principales: Furukawa, Koichi, Nagano, Tatsuya, Tachihara, Motoko, Yamamoto, Masatsugu, Nishimura, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504110/
https://www.ncbi.nlm.nih.gov/pubmed/32859106
http://dx.doi.org/10.3390/molecules25173900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504110/
https://www.ncbi.nlm.nih.gov/pubmed/32859106
http://dx.doi.org/10.3390/molecules25173900

Ejemplares similares